Investigational drug · Phase 2
AltSonflex1-2-3
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diarrhoea.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
3
Any phase or sponsor naming "AltSonflex1-2-3"
First trial start
2021
Oct 6, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AltSonflex1-2-3", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diarrhoea
Largest trials
Live from ClinicalTrials.gov: studies naming "AltSonflex1-2-3" as an intervention, largest first.
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05073003 · 551 participants · Start Oct 6, 2021 · Primary completion Jun 24, 2025
Drug: AltSonflex1-2-3 High Dose; AltSonflex1-2-3 Medium Dose and 4 more · For: Diarrhoea
Sites: Ghent, Belgium; Kericho, Kenya
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06663436 · 200 participants · Start Nov 13, 2024 · Primary completion Oct 21, 2025
Drug: altSonflex1-2-3 Dose A; altSonflex1-2-3 Dose B and 3 more · For: Diarrhoea
Sites: Kericho, Kenya
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African ChildrenPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07320716 · 179 participants (planned) · Start Feb 6, 2026 · Primary completion Oct 16, 2028
Drug: AltSonflex1-2-3; Menveo and 2 more · For: Diarrhoea
Sites: Kericho, Kenya
Newest research
PubMed records naming it or its code names, newest first.
- Immunogenicity evaluation of altSonflex1-2-3 Shigella vaccine across mice, rats, and rabbits to inform human translational insights.
Caradonna V, Alfini R, Pinto M, et al. · Front Immunol 2025
- Evaluation of cross-functional antibody responses elicited by a four-component GMMA Shigella vaccine.
Caradonna V, Sarakinou E, Di Benedetto R, et al. · NPJ Vaccines 2025
- Antibodies elicited by altSonflex1-2-3 GMMA vaccine are bactericidal against a panel of drug-resistant Shigella clinical isolates.
Boero E, Di Benedetto R, Vezzani G, et al. · Front Immunol 2025
- Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.
Leroux-Roels I, Maes C, Mancini F, et al. · J Infect Dis 2024
- Comparison of Shigella GMMA and glycoconjugate four-component formulations in animals.
Di Benedetto R, Mancini F, Caradonna V, et al. · Front Mol Biosci 2023
- A next-generation GMMA-based vaccine candidate to fight shigellosis.
Rossi O, Citiulo F, Giannelli C, et al. · NPJ Vaccines 2023
Also in development for Diarrhoea
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.